Tau protein is involved in various cellular processes, including having a canonical role in
binding and stabilization of microtubules in neurons. Tauopathies are neurodegenerative …

Mass spectrometry-based proteomics empowers deep profiling of proteome and protein
posttranslational modifications (PTMs) in Alzheimer's disease (AD). Here we review the …

The biological processes that are disrupted in the Alzheimer's disease (AD) brain remain
incompletely understood. In this study, we analyzed the proteomes of more than 1,000 brain …

Proteomic studies of human Alzheimer's disease brain tissue have potential to identify
protein changes that drive disease, and to identify new drug targets. Here, we analyse 38 …

The apolipoprotein E (APOE) gene is the strongest genetic risk factor for Alzheimer's
disease and directly influences tauopathy and tau-mediated neurodegeneration. ApoE4 has …

Converging evidence continues to point towards Tau aggregation and pathology formation
as central events in the pathogenesis of Alzheimer's disease and other Tauopathies …

Alzheimer's disease (AD) is an irreversible neurodegenerative disorder that affects more
than 44 million people worldwide. Despite the high disease burden, there is no effective …

Amyloid plaques contain many proteins in addition to beta amyloid (Aβ). Previous studies
examining plaque-associated proteins have shown these additional proteins are important; …

Lysosomal acidification dysfunction has been implicated as a key driving factor in the
pathogenesis of neurodegenerative diseases, including Alzheimer's disease and …

Protein posttranslational modifications (PTMs) refer to the breaking or generation of covalent
bonds on the backbones or amino acid side chains of proteins and expand the diversity of …